Medical Device Market Access: What Value Analysis Committees Actually Want

2026-07-25 · Caduvo Team

FDA clearance doesn’t open hospital doors. Market access does. Learn what value analysis committees expect from medical devices and how to build a go-to-market strategy that wins.

A 510(k) clearance means you can sell. It doesn’t mean hospitals will buy. The difference is market access — the structured work of getting a device into routine clinical use, covered by payers, and approved by the people who control hospital purchasing. That last group, the value analysis committee, stops more device launches than the FDA ever does.

What Medical Device Market Access Actually Covers

Market access is broader than reimbursement. It includes coding, coverage, and payment, as outlined in the medical device reimbursement primer. But for device makers selling into hospitals, market access also means getting past the value analysis committee. Without a clear medical device go to market strategy that addresses both payer and hospital dynamics, even an elegantly designed product will sit on the shelf.

Medtech market access therefore demands evidence for two distinct audiences: payers who update coverage policies, and hospitals that manage their own formularies and contracts. The value analysis committee is the healthcare system’s internal gatekeeper. It’s where clinical value and economic value get weighed side by side.

Inside the Value Analysis Committee

A value analysis committee typically includes supply chain directors, materials management, a physician champion from the relevant specialty, a finance representative, and someone from quality or infection control. They meet regularly, often biweekly, to review a backlog of new product requests.

Their standard process looks like this:

• A clinician submits a request to trial or adopt a new device.
• The committee requests a dossier from the manufacturer, covering clinical evidence, pricing, and operational impact.
• They score the product against a fixed set of criteria, ranging from patient outcomes to ease of integration.
• If the score meets the threshold, they may authorize a limited trial, then revisit after 3–6 months of data collection.

One question a VAC will always ask: “How many of our patients actually need this?” If the volume is low and the per-unit price is high, the cost-to-benefit argument needs to be airtight. They’ll also press on what the device replaces. If it replaces a cheaper supply, you must show downstream savings (fewer complications, reduced length of stay, lower readmission rates) that offset the price difference.

The Evidence Buyers Actually Ask For

VACs rarely settle for an FDA summary. They want comparative clinical data against the current standard of care. Randomized controlled trials help, but most committees will also accept rigorous real-world evidence, especially from a pilot at a similar institution.

The typical evidence package they expect includes:

• Clinical outcomes data: infection rates, complication rates, functional improvements, or any endpoint relevant to the device category.
• Economic analysis: a budget impact model that shows the net cost per case for the first 12 months, including supply costs and offsets from avoided resource use.
• Operational metrics: procedure time, length of stay, readmission rates, training requirements.
• Peer-reviewed publications: at least one study in a recognized journal strengthens credibility, even if it’s a small series.

They’ll also ask for a CPT code or HCPCS code to understand how the device will be billed. If the product requires a new HCPCS code, that timeline becomes part of the access conversation. (For a guide on what an HCPCS code is and how to apply for one, see this post.)

Hospitals rarely accept list price at face value. They’ll expect a per-case cost that fits within their existing DRG or per-diem payment, or a convincing argument for a carve-out. Be ready to walk a finance analyst through the math.

Realistic Go-to-Market Sequencing for a First Device

For a first product, the sequence is almost never regulatory → sales. It looks more like this:

1. FDA clearance or approval. If you’re pursuing a 510(k), selecting the right predicate device sets the evidentiary baseline early.
2. Coding pathway. Identify whether you’ll use an existing CPT Category I code, a Category III code, or apply for a new HCPCS Level II code. Start this early; the coding process can take 6–12 months.
3. Pilot sites. Place the device in 2–3 hospitals willing to generate real-world data. This is where you collect the metrics your VAC dossier will need.
4. Economic modeling. Using pilot data, build a budget impact model and a cost-effectiveness estimate. Tailor it to the payer mix and cost structure of your target accounts.
5. Value analysis committee presentations. Approach committees with a complete dossier: clinical evidence, economic model, operational data, coding/billing clarity, and a proposed pricing structure.
6. Contracting and post-adoption tracking. Once approved, negotiate GPO or local contracts, then track outcomes to validate the model and support renewals.

The gap between FDA clearance and a regular purchase order can stretch 9–15 months. The variable isn’t the technology — it’s the quality of the market access work that precedes the committee’s vote.

Actionable Takeaways

• Map your target VAC’s criteria before your first meeting. Ask the department chief what evidence the committee has accepted before.
• Build a budget impact model based on your own pilot data, not industry averages. Hospital finance teams notice the difference.
• Prepare a dossier that combines clinical data, economic analysis, and billing clarity. Don’t make the committee chase down codes or peer-reviewed studies on their own.
• Engage supply chain early. They’ll tell you about GPO tier expectations and whether a committee trial is even feasible.
• Plan for 6–12 months from clearance to steady orders. Treat this as the market access phase, not a sales delay.

Medical device market access isn’t a handoff from regulatory to commercial. It’s an integrated function that starts months before the FDA decision and continues long after. Value analysis committees reward the manufacturers that show up with answers, not just claims.